Amneal Pharmaceuticals (AMRX)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$17.44-2.41%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · AMRX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||
| Revenues | 3,117.5 | 3,018.8 | 2,794.0 | 2,393.6 | 2,212.3 | 2,093.7 | 1,992.5 | 1,626.4 | 1,663.0 | — |
| Cost of Revenues | 1,891.8 | 1,905.5 | 1,773.5 | 1,573.0 | 1,427.6 | 1,324.7 | 1,329.6 | 1,147.2 | 938.8 | — |
| Gross Profit | 1,225.8 | 1,113.3 | 1,020.4 | 820.6 | 784.7 | 769.0 | 628.4 | 353.0 | 716.4 | — |
| Operating Expenses & Income | ||||||||||
| Selling, General & Admin | 571.9 | 526.8 | 476.4 | 429.7 | 399.7 | 365.5 | 326.7 | 289.6 | 227.8 | — |
| R&D Expenses | 175.6 | 186.2 | 190.7 | 164.0 | 195.7 | 201.8 | 179.9 | 188.0 | 194.2 | — |
| Other Operating Expenses, Total | 8.4 | 5.2 | — | 15.6 | 4.0 | 0.0 | 0.0 | — | — | — |
| Operating Income | 453.9 | 394.1 | 249.3 | 204.4 | (94.9) | 152.7 | 91.2 | (248.7) | (19.7) | — |
| Earnings from Continuing Operations | ||||||||||
| Other Non-Operating Income / Expenses | (252.7) | (254.9) | (304.3) | (244.6) | (153.2) | (121.4) | (126.9) | 28.4 | (183.0) | — |
| Asset Writedown | — | — | — | 30.8 | 13.0 | 0.7 | 2.7 | 46.6 | 39.3 | — |
| EBT, Incl. Unusual Items | 201.2 | 139.2 | (55.0) | (40.3) | (248.1) | 31.4 | (35.8) | (220.2) | (202.7) | — |
| Income Tax Expense | (14.1) | 11.3 | 18.9 | 8.5 | 6.7 | 11.2 | (104.4) | 383.3 | (1.4) | — |
| Net Income | ||||||||||
| Minority Interest | 58.0 | 55.9 | 43.0 | 35.3 | (125.2) | 9.5 | (22.5) | (241.7) | (32.8) | — |
| Net Income | 157.4 | 72.1 | (73.9) | (84.0) | (270.6) | 13.2 | 67.8 | (603.6) | (19.7) | — |
| Per Share | ||||||||||
| Basic EPS | 0.49 | 0.23 | (0.38) | (0.48) | (0.86) | 0.07 | 0.62 | — | — | — |
| Diluted EPS | 0.48 | 0.22 | (0.38) | (0.48) | (0.86) | 0.07 | 0.61 | — | — | — |
| Revenue per Share | 9.50 | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 319.2 | 313.4 | 309.0 | 176.1 | 150.9 | 148.9 | 147.4 | — | — | — |
| Diluted Weighted Avg Shares | 328.1 | 324.8 | 309.0 | 176.1 | 150.9 | 151.8 | 148.9 | — | — | — |
| Supplemental | ||||||||||
| EBIT | 453.9 | 394.1 | 249.3 | 204.4 | (94.9) | 152.7 | 91.2 | (248.7) | (19.7) | — |
| Effective Tax Rate | -7.0% | — | — | -21.0% | -2.7% | 35.7% | 291.7% | -174.0% | 0.7% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.